SEC Filing Summary: Carlyle Group Inc. (Form 13F)
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Carlyle Group Inc. for the reporting period ending March 31, 2024. The document discloses the equity securities held by the investment manager as of the end of the quarter. It does not contain financial performance data (revenue, profit, cash flow) for Carlyle Group Inc. itself, but rather a snapshot of its investment portfolio.
Key Financial Metrics and Portfolio Composition
The filing lists 31 equity positions. The total value of the reported holdings is not explicitly summed in the text, but individual position values are provided in Column 5. Key portfolio characteristics include:
- Largest Position by Value: ZoomInfo Technologies Inc. ($420,698,919).
- Second Largest Position by Value: Quidelortho Corp ($597,341,173).
- Third Largest Position by Value: Soleno Therapeutics Inc ($173,122,816).
- Investment Authority: All listed positions are reported with "Sole" discretionary authority (Column 7).
- Derivatives: No Put or Call options are reported in Columns 6 and 7 for these positions.
Material Changes and Portfolio Activity
As a quarterly snapshot, this filing does not provide comparative data against the prior period (December 31, 2023) within the text provided. Therefore, specific material changes in share counts or values versus the prior quarter cannot be calculated from this document alone. The filing indicates the current holdings as of March 31, 2024.
Guidance, Outlook, and Risks
Management Commentary: None. Form 13F filings are statutory disclosures of holdings and do not include management commentary, guidance, or outlook.
Risks and Contingencies: The filing includes a standard disclaimer stating that the SEC has not reviewed the information for accuracy or completeness. The portfolio shows significant concentration in specific sectors, particularly biotechnology and technology (e.g., Adicet Bio, Soleno Therapeutics, ZoomInfo, Quidelortho), which implies sector-specific volatility risks.
Important Facts for Investor Verification
- Top Holdings: Verify the current market price of ZoomInfo Technologies and Quidelortho Corp, as these two positions represent the largest portion of the disclosed portfolio value.
- Biotech Exposure: Note the significant number of positions in biotechnology and pharmaceutical companies (e.g., Adicet Bio, Effector Therapeutics, Phathom Pharmaceuticals, Soleno Therapeutics), which may carry higher regulatory and clinical trial risks.
- Share Counts vs. Value: Some positions show high share counts but lower total values (e.g., GDS Hldgs Ltd with 27M shares valued at ~$27M), indicating lower per-share prices compared to high-value positions like ZoomInfo.
- Missing Data: This filing does not provide Carlyle Group's own revenue, profit, or debt levels; investors must refer to Carlyle's 10-Q or 10-K filings for that information.